GH Research (GHRS)
9.05
0.35 (4.02%)
At close: Apr 17, 2025, 3:59 PM
9.10
0.55%
After-hours: Apr 17, 2025, 04:05 PM EDT
4.02% (1D)
| Bid | 8.5 |
| Market Cap | 561.35M |
| Revenue (ttm) | 80K |
| Net Income (ttm) | -38.96M |
| EPS (ttm) | -0.75 |
| PE Ratio (ttm) | -12.07 |
| Forward PE | -5.92 |
| Analyst | Buy |
| Ask | 10.5 |
| Volume | 180,187 |
| Avg. Volume (20D) | 523,850 |
| Open | 8.96 |
| Previous Close | 8.70 |
| Day's Range | 8.73 - 9.18 |
| 52-Week Range | 6.00 - 20.50 |
| Beta | 0.85 |
About GHRS
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 25, 2021
Employees 50
Stock Exchange NASDAQ
Ticker Symbol GHRS
Website https://www.ghres.com
Analyst Forecast
According to 7 analyst ratings, the average rating for GHRS stock is "Buy." The 12-month stock price forecast is $32, which is an increase of 253.59% from the latest price.
Stock Forecasts2 months ago
-9.28%
GH Research shares are trading lower after announc...
Unlock content with
Pro Subscription
2 months ago
+69.72%
GH Research shares are trading higher after the company's inhalable depression treatment GH001 met the primary endpoint in its Phase 2b trial, showing symptom reduction.
